M 4 E Common Technical Document for the …
© emea 2006 3 common technical document for the registration of pharmaceuticals for human use: efficacy clinical overview and clinical summary of module 2
Download M 4 E Common Technical Document for the …
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
United States Court of Appeals for the Federal Circuit
intellirights.comUnited States Court of Appeals for the Federal Circuit _____ ELI LILLY AND COMPANY, Plaintiff-Cross Appellant, v. TEVA PHARMACEUTICALS USA, INC.,
Immune Globulin Intravenous (Human) 5% …
www.abopharmaceuticals.comImmune Globulin Intravenous (Human) 5% Solvent/Detergent Treated . OCTAGAM® U.S. License No. 1646 . Rx only . DESCRIPTION . lmmune Globulin Intravenous (Human) [IGIV], OCTAGAM, is a solvent/detergent
AcuDial - Diastat
www.diastat.comDiastat® C-IV (diazepam rectal gel) Rectal Delivery System Diastat® AcuDial™ C-IV (diazepam rectal gel) Rectal Delivery System Rx Only WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS
Guideline on strategies to identify and mitigate …
www.ema.europa.euFirst-in-human, phase I, early clinical trials, investigational medicinal product, risk mitigation, integrated protocols, multiple ascending dose, dose escalation.
Clinical Pharmacokinetic Studies of Pharmaceuticals
www.nihs.go.jp- 1 - Clinical Pharmacokinetic Studies of Pharmaceuticals This document is an informal translation of the official text that was promulgated in Japanese on